Close monitoring of pulmonary complications, particularly in the early stages of the disease, for all ATA-positive SSc patients—regardless of the SSc subset—may facilitate early treatment and help prevent the extensive progression of pulmonary complications. The gene discussed is ATM; the disease is systemic sclerosis.